Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
Publishing timestamp: 2024-04-30 11:04:23
Summary
Eli Lilly reported strong first-quarter results, with adjusted profit beating expectations. The company hiked its full-year guidance due to strong sales of its diabetes drug Mounjaro and weight loss treatment Zepbound. The company expects significant production increases in the second half of the year. Despite some sales missing expectations, Eli Lilly's stock jumped more than 5% on the news.
Sentiment: POSITIVE
Tickers: LLY,
Keywords: business, eli lilly and co, business news, breaking news, pharmaceuticals, united states, david a. ricks, health care industry, biotech and pharmaceuticals, earnings, biotechnology,
Source: https://www.cnbc.com/2024/04/30/eli-lilly-lly-earnings-q1-2024.html